SCHEMBL4692890

SCHEMBL4692890

C[Si](C)(C)CCOCn1cnc2c1-c1ccccc1Oc1ccccc1-2

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.34
CREBBP Q92793 1/20 0.34
DGAT1 O75907 3/20 0.33
ALOX5AP P20292 2/20 0.31
FEN1 P39748 2/20 0.31
LMNA P02545 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
EGFR P00533 1/20 0.31
IGF1R P08069 1/20 0.31
SRC P12931 1/20 0.31
FLT4 P35916 1/20 0.31
KDR P35968 1/20 0.31
FLT3 P36888 1/20 0.31
EPHB4 P54760 1/20 0.31
TEK Q02763 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4697520 0.89 MAPK1 (0.39) BRD4CREBBPLMNASMN1; SMN2CYP1A2
SCHEMBL4695367 0.89 MAPK1 (0.39) BRD4CREBBPLMNASMN1; SMN2CYP1A2
SCHEMBL4697528 0.81 BRD4 (0.34) BRD4CREBBPDGAT1ALOX5APFEN1
SCHEMBL4064723 0.76 PTGS2 (0.50) DGAT1LMNA
SCHEMBL4697521 0.75 LMNA (0.39) BRD4CREBBPLMNACYP1A2CYP2D6
SCHEMBL4695913 0.74 LMNA (0.38) BRD4CREBBPLMNACYP1A2CYP2D6
SCHEMBL4502812 0.74 NPC1 (0.33) DGAT1NPC1
SCHEMBL4696747 0.74 NPC1 (0.34) LMNASMN1; SMN2NPC1
SCHEMBL4692865 0.73 NPC1 (0.34) NPC1
SCHEMBL30013328 0.72 SMN1; SMN2 (0.56) LMNASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1509528-B1 1,3-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF GLAXOSMITHKLINE ZAGREB (HR) 2008-09-24 EP disclosed
US-7166583-B2 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2007-01-23 US disclosed
US-20050227963-A1 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227963-A1 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof IL1A, TNF, IL1B BRD4 2351/4885CREBBP 3008/4885DGAT1 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.